Figure 5
From: Ibrutinib does not prevent kidney fibrosis following acute and chronic injury
Effect of Ibrutinib on human PBMC treated with myoglobin or uromodulin. Concentration (pg/ml) of IL-1β assessed by ELISA in culture supernatant of human PBMC treated with Uromodulin (Umod, A) or Myoglobin (Myo, B) and with ibrutinib (Ibru) or vehicle (Veh). Data expressed as mean ± SEM, n = 4–12, *p < 0.05, ****p < 0.001 compared with the Veh or Ctl group (ANOVA Tukey’s test; n = 3–15 samples per group); ns, not significant.
